Transparency

NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

NASHP’s Center for State Rx Drug Pricing seeks a partner to provide technical and strategic expertise to help a workgroup of state officials from California, Nevada, Oregon, Connecticut, and Vermont implement their drug cost transparency laws and help Maine and New Hampshire develop transparency programs as mandated by recent legislation. This work will help all […]

Read More
  • Twenty-Four States Passed 37 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session
    State Health Policy Blog

    Despite a short legislative season, state lawmakers across the country introduced an unprecedented 160 bills to stem the rising cost of prescription drugs and have enacted 37 into law — with seven state legislatures still in session. Last year, state legislatures introduced 100 Rx cost control bills and passed 27. Register Now to Attend NASHP’s […]

    Read More
  • A Glossary of All Terms Pharma

    If you’re working to control the cost of prescription drugs, you need to know the lingo used by the pharmaceutical industry. Below is a glossary of terms commonly used by players in the drug research, regulation, manufacturing, distribution, and purchasing worlds. Drug Product Terms Brand product: Branded products are not generic drugs or products. A brand can be […]

    Read More
  • States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing
    State Health Policy Blog

    Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. These laws are an important first step to shine a light on why drug prices are rapidly climbing. To address a problem, state health policymakers need to understand it, but transparency laws don’t yet give […]

    Read More
  • Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation
    Publications

    As the number of state bills to rein in prescription drug prices grows beyond 150 nationwide in 2018, the first generation of several state laws passed last year are now before the courts. The pharmaceutical industry has consistently challenged drug cost transparency and price gouging legislation passed in 2017 in federal courts. How well these […]

    Read More
  • An Oregon State Lawmaker Crafts a Winning Strategy for Transparency Legislation

    Last week, Oregon Gov. Kate Brown signed a drug cost transparency bill into law that requires drug makers to report the reasons behind dramatic drug price increases. The bill’s leading advocate and architect, state Rep. Robert Nosse, D-Portland, worked for nearly three years to create a prescription cost containment bill that would win bipartisan support […]

    Read More
  • State Legislatures Start Out Strong in 2018 with Bills to Curb Rx Drug Costs
    State Health Policy Blog

    With the federal government continuing to take no action to curb drug costs, states legislatures across the country are intensifying their efforts in 2018 to staunch the financial hemorrhage to health care budgets caused by escalating prescription drug costs. Three weeks into 2018, 43 bills designed to rein in prescription drug costs have been introduced […]

    Read More
  • State Legislative Action to Lower Pharmaceutical Costs
    Maps

    *Updated Sept. 5, 2018* Find the status of state legislation to curb prescription drugs below. Use the category button to search by type of legislation or click on a state to view its drug bills. Click here to view a chart listing legislation by state. View state action in 2017 and 2015-2016. Know about a bill to add or have information to […]

    Read More
  • Reining in Rx Drug Costs: What States Achieved in 2017 and Where They’re Heading in 2018
    State Health Policy Blog

    In a year of tense partisan debate over the future of health care, one issue has achieved rare bipartisan agreement — the need to curb rising prescription drug costs. Polls show again and again that Americans, regardless of political affiliation, view the high costs of drugs as one of their chief health care concerns. Reviews […]

    Read More
  • The National Academy of Sciences recently released a report recommending several strategies to curb prescription drug costs that attempt to strike a balance between reining in prices while fostering continued drug development and innovation. Several of the academy’s recommendations are already getting trial runs in states, which are experimenting with innovative cost-savings approaches in order […]

    Read More